A dysglycaemic effect of statins in diabetes: Relevance to clinical practice?

Diabetologia

Volumn 57, Issue 12, 2014, Pages 2433-2435

  Swerdlow, Daniel I ^a   Sattar, Naveed ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular disease; Dysglycaemia; HbA1c; Meta analysis; Prevention; Statins; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; GLUCOSE BLOOD LEVEL;

ANTIDIABETIC ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; BLOOD; CHEMICALLY INDUCED;

BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84926654819     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3409-3     Document Type: Article

References (20)

1. Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735-742
2. Preiss D, Seshasai SRK, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305: 2556-2564
3. Carter AA, Gomes T, Camacho X et al (2013) Risk of incident diabetes among patients treated with statins: population based study. BMJ 346: f2610
4. Navarese EP, Buffon A, Andreotti F et al (2013) Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 111: 1123-1130
5. Danaei G, García Rodríguez LA, Fernandez Cantero O, Hernán MA (2013) Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 36: 1236-1240
6. Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 376: 1670-1681
7. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J et al (2012) The effects of lowering LDL cholesterolwith statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380: 581-590
8. Kearney PM, Blackwell L, Collins R et al (2008) Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117-125
9. Sattar N, Taskinen M-R (2012) Statins are diabetogenic-myth or reality? Atheroscler SUPPL 13: 1-10
10. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV (2014) HMG-Co A reductase inhibition, type 2 diabetes and body weight: evidence from genetic analysis and randomised trials. Lancet. doi: 10. 1016/S0140-6736(14)61183-1
11. Holmes MV, Lange LA, Palmer T et al (2014) Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet 94: 198-208
12. Erqou S, Lee CC, Adler AI (2014) Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. doi: 10. 1007/s00125-014-3374-x
13. Emerging Risk Factors Collaboration, Seshasai SRK, Kaptoge S et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364: 829-841
14. Stone NJ, Robinson JG, Lichtenstein AH et al (2014) 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129: S1-S45
15. NICE (2014) Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. National Institute for Health and Care Excellence, London. Available from www. nice. org. uk/guidance/cg181, accessed 26 September 2014
16. JBS3 Board (2014) Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart Br Card Soc 100(SUPPL 2): ii1-ii67
17. Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412
18. ORIGIN Trial Investigators, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319-328
19. Sattar N (2013) Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 56: 686-695
20. Cooper-De Hoff RM, Pacanowski MA, Pepine CJ (2009) Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol 53: S28-S34